Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses
Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot of people worldwide, resulting in COVID-19 vaccines being developed as an effort to stop the pandemic. The vaccines approved by the Mala...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/60291/ http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf |
| _version_ | 1848884405817311232 |
|---|---|
| author | Izani, Wani Husna Mohd |
| author_facet | Izani, Wani Husna Mohd |
| author_sort | Izani, Wani Husna Mohd |
| building | USM Institutional Repository |
| collection | Online Access |
| description | Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot
of people worldwide, resulting in COVID-19 vaccines being developed as an effort to
stop the pandemic. The vaccines approved by the Malaysian government include
Sinovac CoronaVac and Pfizer-BioNTech BNT162b2. Vaccination can increase the
level of neutralising antibodies and protect against COVID-19 infections. Neutralising
antibodies are essential in monitoring the effectiveness of the vaccines against SARSCoV-
2. Several assays have been developed to detect neutralising antibody titres in
individuals. The purpose of this study was to evaluate the two commercialized assays,
GenScript cPass and ImmuSAFE COVID+ tests in detecting SARS-CoV-2
neutralising antibody titres. Both assays used a total of 26 serum samples of
CoronaVac second (n = 13) and BNT162b2 booster (n = 13) doses. The study also
determined neutralising antibody titres between males and females among young
adults in second and booster doses. The results showed the titre of neutralising
antibodies was higher in BNT162b2 booster dose than in CoronaVac second dose
serum samples. The analysis of the demographic data showed neutralising antibody
titres in females were higher than in males among young adults in second and booster
dose samples. The study concluded that both assays were reliable in detecting
neutralising antibodies in serum samples following vaccination. |
| first_indexed | 2025-11-15T19:06:11Z |
| format | Thesis |
| id | usm-60291 |
| institution | Universiti Sains Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T19:06:11Z |
| publishDate | 2023 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | usm-602912024-04-18T04:31:10Z http://eprints.usm.my/60291/ Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses Izani, Wani Husna Mohd R Medicine RA440-440.87 Study and teaching. Research RC109-216 Infectious and parasitic diseases Coronavirus disease 2019 (COVID-19) outbreak in 2020 was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic has affected a lot of people worldwide, resulting in COVID-19 vaccines being developed as an effort to stop the pandemic. The vaccines approved by the Malaysian government include Sinovac CoronaVac and Pfizer-BioNTech BNT162b2. Vaccination can increase the level of neutralising antibodies and protect against COVID-19 infections. Neutralising antibodies are essential in monitoring the effectiveness of the vaccines against SARSCoV- 2. Several assays have been developed to detect neutralising antibody titres in individuals. The purpose of this study was to evaluate the two commercialized assays, GenScript cPass and ImmuSAFE COVID+ tests in detecting SARS-CoV-2 neutralising antibody titres. Both assays used a total of 26 serum samples of CoronaVac second (n = 13) and BNT162b2 booster (n = 13) doses. The study also determined neutralising antibody titres between males and females among young adults in second and booster doses. The results showed the titre of neutralising antibodies was higher in BNT162b2 booster dose than in CoronaVac second dose serum samples. The analysis of the demographic data showed neutralising antibody titres in females were higher than in males among young adults in second and booster dose samples. The study concluded that both assays were reliable in detecting neutralising antibodies in serum samples following vaccination. 2023-08 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf Izani, Wani Husna Mohd (2023) Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses. Masters thesis, Universiti Sains Malaysia. |
| spellingShingle | R Medicine RA440-440.87 Study and teaching. Research RC109-216 Infectious and parasitic diseases Izani, Wani Husna Mohd Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody titres in coronavac second and BNT162b2 booster doses |
| title | Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and BNT162b2 booster doses |
| title_full | Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and BNT162b2 booster doses |
| title_fullStr | Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and BNT162b2 booster doses |
| title_full_unstemmed | Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and BNT162b2 booster doses |
| title_short | Evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and BNT162b2 booster doses |
| title_sort | evaluation of genscript cpass and immusafe covid+ assays in detection of sars-cov-2 neutralising antibody
titres in coronavac second and bnt162b2 booster doses |
| topic | R Medicine RA440-440.87 Study and teaching. Research RC109-216 Infectious and parasitic diseases |
| url | http://eprints.usm.my/60291/ http://eprints.usm.my/60291/1/Wani%20Husna%20Mohd%20Izani-E.pdf |